Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Public ClinicalTrials.gov record NCT00511459. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment of subjects with Her2-negative metastatic or locally recurrent breast cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.
Study identification
- NCT ID
- NCT00511459
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 228 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2007 (Type not available)
- Primary completion
- Aug 2010 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- Oct 29, 2015
2007 – 2014
United States locations
- U.S. sites
- 26
- U.S. states
- 14
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Litchfield Park | Arizona | 85340 | — |
| Research Site | Tucson | Arizona | 85724 | — |
| Research Site | Hot Springs | Arkansas | 71913 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Campbell | California | 95008 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Murrieta | California | 92562 | — |
| Research Site | Santa Maria | California | 93454 | — |
| Research Site | New Haven | Connecticut | 06520 | — |
| Research Site | Stamford | Connecticut | 06902 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Robbinsdale | Minnesota | 55422 | — |
| Research Site | Henderson | Nevada | 89052 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | Nashua | New Hampshire | 03061 | — |
| Research Site | Edison | New Jersey | 08820 | — |
| Research Site | Mountain Lakes | New Jersey | 07046 | — |
| Research Site | Asheville | North Carolina | 28806 | — |
| Research Site | Charlotte | North Carolina | 28203 | — |
| Research Site | Hershey | Pennsylvania | 17033 | — |
| Research Site | Philadelphia | Pennsylvania | 19106 | — |
| Research Site | Columbia | South Carolina | 29210 | — |
| Research Site | Richardson | Texas | 75080 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Sugar Land | Texas | 77479 | — |
| Research Site | Ogden | Utah | 84403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00511459, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2015 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00511459 live on ClinicalTrials.gov.